Kaken Pharmaceutical Co (KKPCF) Financial Statements
Kaken Pharmaceutical Co Financial Overview
Kaken Pharmaceutical Co's market cap is currently $873.90M. The company's EPS TTM is $333.12; its P/E ratio is 14.06; and it has a dividend yield of 4.85%. Kaken Pharmaceutical Co is estimated to report earnings on November 9, 2026, and the estimated EPS forecast is $-0.03. See an overview of income statement, balance sheet, and cash flow financials.
| Mar 26 | Mar 26 | Mar 25 | Mar 24 | Mar 23 | |
|---|---|---|---|---|---|
| Income Statement | |||||
| Total Revenue | $ 94.03B | $ 76.87B | $ 72.04B | $ 72.98B | $ 76.03B |
| Gross Profit | $ 58.26B | $ 39.24B | $ 38.54B | $ 39.56B | $ 41.58B |
| Operating Income | $ 21.04B | $ -899.00M | $ 9.51B | $ 8.00B | $ 17.06B |
| EBITDA | $ 22.02B | $ 5.68B | $ 12.57B | $ 9.40B | $ 16.38B |
| Net Income | $ 13.95B | $ 2.14B | $ 8.03B | $ 5.44B | $ 9.55B |
| Balance Sheet | |||||
| Cash & Short-Term Investments | $ 70.08B | $ 50.70B | $ 65.32B | $ 74.26B | $ 74.62B |
| Total Assets | $ 190.42B | $ 178.22B | $ 171.62B | $ 166.33B | $ 165.18B |
| Total Debt | $ 3.85B | $ 3.85B | $ 3.85B | $ 3.85B | $ 3.85B |
| Net Debt | $ -50.24B | $ -40.86B | $ -46.77B | $ -55.71B | $ -57.17B |
| Total Liabilities | $ 37.78B | $ 30.59B | $ 27.87B | $ 29.49B | $ 26.85B |
| Stockholders' Equity | $ 152.63B | $ 147.62B | $ 143.75B | $ 136.26B | $ 137.75B |
| Cash Flow | |||||
| Free Cash Flow | $ 25.64B | $ -14.07B | $ 716.00M | $ 7.27B | $ 10.35B |
| Operating Cash Flow | $ 29.78B | $ -11.08B | $ 2.58B | $ 9.25B | $ 13.34B |
| Investing Cash Flow | $ -19.65B | $ 315.00M | $ -5.85B | $ -2.63B | $ -7.89B |
| Financing Cash Flow | $ -5.37B | $ -8.84B | $ -5.66B | $ -6.99B | $ -8.13B |
Currency in JPY
